The interest in CD38 as a tumor-promoting molecule has grown as more research expands the field, originating in hematological diseases such as chronic lymphocytic leukemia (CLL) and multiple myeloma, but now blossoming into multiple types of solid tumors. This evidence concerns the gene CD38 and plasma cell myeloma.